Bristol Myers Squibb (NYSE:BMY) Upgraded to Strong-Buy at Zacks Research

Key Points

• Zacks Research upgraded Bristol Myers Squibb to “strong buy” from “hold” and raised several future earnings estimates, including FY2027 EPS of $6.24 and FY2028 EPS of $5.23.
• Bristol Myers Squibb recently beat quarterly expectations, reporting $2.04 EPS versus the $1.60 consensus and $12.97 billion in revenue versus $11.74 billion expected. Revenue increased 5.7% year over year, and the company maintained FY2026 EPS guidance of $6.75–$7.00.
• Analyst sentiment is broadly positive, with a “Moderate Buy” consensus and an average price target of $67.06, though investors remain concerned about patent expirations and declining sales from established blockbuster drugs.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) was upgraded by investment analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a report released on Wednesday, Zacks reports. Zacks Research also issued estimates for Bristol Myers Squibb's Q3 2027 earnings at $1.56 EPS, FY2027 earnings at $6.24 EPS, Q1 2028 earnings at $1.48 EPS, Q2 2028 earnings at $1.38 EPS and FY2028 earnings at $5.23 EPS.

A number of other research analysts have also recently commented on the company. Wells Fargo & Company set a $65.00 price target on Bristol Myers Squibb and gave the stock an "equal weight" rating in a report on Friday, July 31st. Citigroup reaffirmed a "neutral" rating and issued a $70.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, August 3rd. Wall Street Zen upgraded Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 27th. Roth Capital began coverage on shares of Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a "buy" rating and a $75.00 target price for the company. Finally, Raymond James Financial began coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a "strong-buy" rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $67.06.

Bristol Myers Squibb Trading Up 0.6%

Shares of Bristol Myers Squibb stock opened at $61.54 on Wednesday. Bristol Myers Squibb has a fifty-two week low of $42.52 and a fifty-two week high of $68.64. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. The company has a market capitalization of $125.71 billion, a P/E ratio of 13.56, a P/E/G ratio of 0.30 and a beta of 0.23. The company has a fifty day moving average of $64.44 and a 200 day moving average of $60.15.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business's revenue was up 5.7% on a year-over-year basis. During the same period in the previous year, the business earned $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, sell-side analysts anticipate that Bristol Myers Squibb will post 6.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Phil M. Holzer sold 500 shares of the firm's stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.05% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of BMY. Davis Asset Management L.P. bought a new position in Bristol Myers Squibb during the 2nd quarter valued at about $27,000. Bayban bought a new stake in Bristol Myers Squibb in the fourth quarter worth about $31,000. Addison Advisors LLC bought a new stake in Bristol Myers Squibb in the second quarter worth about $32,000. Groupe la Francaise boosted its position in shares of Bristol Myers Squibb by 562.9% during the second quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company's stock valued at $33,000 after buying an additional 501 shares during the period. Finally, Arlington Trust Co LLC bought a new position in shares of Bristol Myers Squibb during the second quarter valued at approximately $35,000. Institutional investors own 76.41% of the company's stock.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Zacks Research modestly raised its earnings forecasts for Bristol Myers Squibb, increasing estimates for third-quarter 2027 EPS to $1.56, full-year 2027 EPS to $6.24, first- and second-quarter 2028 EPS to $1.48 and $1.38, respectively, and full-year 2028 EPS to $5.23 from $5.17. The revisions suggest slightly improved expectations for the company’s future earnings. Zacks Research estimates
• Positive Sentiment: BMY was added to Zacks’ Rank #1 Strong Buy list and its Strong Buy income-stock list. The ratings may support demand for the shares, particularly because Bristol Myers Squibb offers significant cash flow and an attractive dividend profile. Zacks Strong Buy list
• Positive Sentiment: The company selected Onco360 as a restricted specialty-pharmacy provider for ZENBEXUS (iberdomide), its newly approved multiple-myeloma treatment. The distribution arrangement and clinical support could help the drug reach eligible patients during its commercial rollout. ZENBEXUS pharmacy network
• Positive Sentiment: Bristol Myers Squibb completed a Phase 1 lung-cancer combination study, providing incremental support for its immuno-oncology pipeline. Analysts also highlighted newer medicines as increasingly important in offsetting declines from mature products. Lung cancer study update
• Negative Sentiment: Despite the near-term positives, investors remain concerned about patent expirations and declines in established blockbuster products. Longer-term Zacks estimates remain below current-year expectations, underscoring the need for newer drugs such as ZENBEXUS to replace lost revenue.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.